Parameter
| Biomarker | miR-223 / miR-503-5p | Full name | MicroRNA-223 / MicroRNA-503-5p | Molecular Type | Nucleic acid (RNA) |
|---|---|---|---|---|---|
| Molecular Formula | Molecular Weight | ~22 nt (~6.6 kDa each) | Core Functional Dimensions | Subtype classification, inflammation assessment | |
| Disease | Heart failure | Disease Subtypes | / | ||
| Organ | Myocardium, immune cells | Test Sample / Technology Platform | Plasma (RT-qPCR, Olink RNA panel) | ||
| Pathobiological Mechanisms | miR-223 inhibits myocardial fibrosis and is highly expressed in HFpEF. miR-503-5p distinguished HFrEF from HFpEF | ||||
| Clinical Availability Status | Research validation: - Wong, such studies have shown that 8-micrornas panel (including miR-503-5p) to distinguish HFrEF from HFpEF AUC = 0.88; -Mir-223 was positively correlated with hs-CRP in HFpEF (r=0.45) | ||||
| Notes and Dynamics | 8-micrornas panel (miR-503-5p, miR-193-a-5p) associated with the NT-proBNP subtype can correct the 27% to 93% HF miscalculation; MiR-223 in the expression level is 2.3 times that of HFrEF HFpEF and pulmonary vascular resistance (PVR) positive correlation (r = 0.50); It can be used as an indicator to monitor the efficacy of anti-inflammatory therapy (such as Ziltivekimab) for HFpEF | ||||